Tetrahydrouridine
Sponsors
University of Miami, Brian Lally, City of Hope Medical Center, Case Comprehensive Cancer Center, Yogen Saunthararajah
Conditions
Adult Acute Myeloid LeukemiaAggressive B-cell LymphomaBrain and Central Nervous System TumorsHead and Neck CancerHealthyIndolent B-cell LymphomaLung CancerMetastatic Pancreatic Adenocarcinoma
Early Phase 1
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies
CompletedNCT02846935
Start: 2017-04-25End: 2018-01-22Updated: 2019-01-07
p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer
CompletedNCT02847000
Start: 2016-12-20End: 2017-10-30Updated: 2019-01-09
Phase 1
Cytochlor and Tetrahydrouridine as Radiosensitizers and Cisplatin Combined With Radiation Therapy in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity (Mouth) or Oropharynx (Throat)
CompletedNCT00077051
Start: 2004-04-30End: 2007-07-31Updated: 2016-12-15
Cytochlor, Tetrahydrouridine, and External-Beam Radiation Therapy in Treating Patients With Cancer That Has Spread to the Brain
CompletedNCT00521183
Start: 2007-06-30End: 2014-05-31Updated: 2014-11-25
5-Fluoro-2'-Deoxycytidine and Tetrahydrouridine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
CompletedNCT01041443
Start: 2009-12-31End: 2013-10-31Updated: 2015-06-08
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
CompletedNCT05816356
Start: 2023-03-24End: 2023-10-10Updated: 2025-05-22